Cell-Surface Vimentin (CSV) Monoclonal Antibody


Vimentin, a 57kDa type III intermediate filament, is responsible for architecture of cytoplasm.1 As a popular intracellular epithelial mesenchymal transition (EMT) marker, overexpression of vimentin in cancer cells is known for its high correlation to cancer progression. Apart from vimentin’s intracellular functions, recruitment of vimentin to cell surface, also known as cell-surface vimentin (CSV), has been identified to mechanistically participate in cell adhesion, migration and cellular signaling.2

The significance of CSV has been demonstrated in autoimmune disorders, viral infection and cancer progression. Expression of CSV on activated macrophages, platelets and apoptotic T lymphocytes evidenced its participation to human neutrophil spontaneous apoptosis and further corroborated its association with inflammatory diseases and signalings.3 As a putative anti-viral drug target, CSV takes part in viral multiplication by facilitating the internalization of virions.4 Furthermore, studies have identified CSV as cancer specific EMT marker. CSV expression is shown to have correlated with metastatic phenotypes in aggressive cancer and sarcoma. Due to vimentin’s unique characteristics of translocating from intracellular to extracellular region in cells undergoing EMT, detection and identifying cells expressing CSV demonstrated high specificity in isolating cancer cells.5,6,7 Recent advances explored the possibility of leveraging CSV’s distinctiveness in cancer therapy.8 CSV targeted therapy successfully increased caspase-3 activity and induced cancer cell apoptosis. With such a success and impact on the oncology community, clinical research advances in CSV study is expected to excel.

Abnova obtains worldwide exclusive license of the patented CSV monoclonal antibody, clone 84-1, from MD Anderson Cancer Center, United States. This antibody has been validated for its intended use in majorities of cancer cell lines by both immunofluoresence and flow cytometry.9 As a sole provider for this powerful tool, Abnova hopes to propel the investigations on cancer research with specificity and broad applicability.

CSV monoclonal antibody, clone 84-1 (H00007431-M08)

Characterizations of CSV



Clinical Applications of CSV monoclonal antibody

Circulating Tumor Cell (CTC) isolation using CytoQuest™ CR


Pancreatic Cancer
Cell-Surface Vimentin as Novel Epithelial-Mesenchymal Transition and Cancer Stem Cell Biomarkers for Pancreatic Cancer Circulating Tumor Cells
Ovarian Cancer
Compare EpCAM PanCK and CSV CSV Antibody Capture and Detection of Ovarian Papillary Serous Cystadenocarcinoma
Prostate Cancer
Cell-Surface Vimentin Transformed EMT CTCs and CSCs in Metastatic Castration-Resistant Prostate Cancer
Lung Cancer
Cell-Surface Vimentin and Pan Cytokeratin Positive Circulating Tumor Cells in Pleural Effusion of Lung Adenocarcinoma Patient
Glioblastoma Multiforme
GFAP and EGFRvIII Detection of Glioblastoma Multiforme Circulating Tumor Cells Captured by Cell-Surface Vimentin Antibody
Cell-Surface Vimentin Antibody for Postive Microfluidic Enrichment and Enumeration of Neuroblastoma CTCs and DTCs

Circulating Stem Cell (CSC) isolation using CytoQuest™ CR


Prostate Cancer
Cell-Surface Vimentin Transformed EMT CTCs and CSCs in Metastatic Castration-Resistant Prostate Cancer
Glioblastoma Multiforme
Isolation of DBA Positive Circulating Cancer Stem Cells in Glioblastoma Multiforme


Expression of CSV in EMT cells

Detection of CSV on Human Colorectal Cancer Cells
Circulating tumor cells derived from colorectal cancer patients were stained for nucelus (blue), cell surface vimentin (green,  H00007431-M08) and specific EMT biomarkers (red), including FOXC2, TWIST-2, SNAIL, SLUG, EpCAM and E-cadherin6.

CSV expression profile in various cell lines

Cell Line CSV Cell Line CSV Cell Line CSV
Breast   Bone   Liver  
  MCF-7 (H) +   OS-25 (H) ++   AMC14 (M) ++
  SKBR3 (H) +   HOS (H) ++ Colon  
  MDA-MB-231 (H) +   MG-263 (H) ++   DLD-1 (H) ++
  MDA-MB-453 (H) +   LM7 (H) +   GEO (H) ++
  MDA-MB-458 (H) ++   SAOS-2 (H) +   OS-187 (H) ++
  4T1 (M) +   OS25 (H) +   SW620 (H) +
Brain     OS-O (H) ++   SW480 (H) +
  SKNAS (H) ++   OS-D (H) +   HCT-116 (H) +
  SKNBE2 (H) +++   U2OS (H) +   HT-29 (H) ++
  NGP (H) +   CCH-OSD (H) +   Caco-2 (H) +
  SH-SY5Y (H) ++   K7 (M) ++   CT-26 (M) +
  LAN5 (H) ++   K7M2 (M) +++ Pancreas  
  KCN (H) +   DUNN (M) +   PANC-1 (H) ++
  DBT (M) +   LM8 (M) +++   MiaPACA-2 (H) +
  U251 (H) +   OST-DL-391 + Other  
Bladder     OST-DL-393 +   FBL3 (M) +++
  RT4V6 (H) +   OST-DL-396a ++   SCCVII (M) +
  T24 (H) ++        

Cell surface staining of CSV

Analysis of CSV-specific 84-1 monoclonal antibody
Cell surface staining of CSV in LM7 (osteosarcoma) cancer cell line using confocal microscopy. Cells were stained for CSV (green), WGA (red) and nucleus DRAQ5 (blue). CSV monoclonal antibody 84-1  (H00007431-M08) co-localized with WGA indicated cell surface vimentin.5
Detection of CSV in HPC-1-derived Spheres on Geltrex-coated Wells
Vimentin (green, H00007431-M08) was detected at the periphery of 3-dimensional HPC-derived sphere model. Since cells at periphery were more aggressive, the invasive phenotype correlated with increase nuclear accumulation of β-catenin (red).6

Flow Cytometry analysis of CSV on sarcoma, colorectal cancer, breast cancer and pancreatic cancer cells

CSV Expression in Cancer Cell Lines
Immunological assessment of CSV in various cancer cell lines and normal cell lines using flow cytometry in which only cancer cells, including GEO (colorectal cancer), MDA-MB-231 (breast cancer) and PANC-1 (pancreatic cancer) can be detected by CSV, 84-1 (H00007431-M08)6.
CSV Expression in Sarcoma Cell Lines
Immunological assessment of CSV in various cancer cell lines and normal cell lines using flow cytometry in which only cancer cells, including SKNBE-2 (neuroblastoma), RH-41 (rhabdomyosarcoma) and LM7 (osteosarcoma) can be detected by CSV, 84-1 (H00007431-M08)5.
Sorting of Hepatocellular Carcinoma Cells (HCC)
Stem-cell liked cancer cell populations, csVim+ CD133- and csVim- CD133+, were isolated and sorted into sub-G1, G1, S and G2 phases from primary HCC using CSV, 84-1 (H00007431-M08)7.

1. Mitra, A. and Li, S. (2014). J Cancer Prev Curr Res. DOI: 10.15406/jcpcr.2014.01.00014
2. Satelli, A. and Li, S. (2011). Cell Mol Life Sci. DOI: 10.1007/s00018-011-0735-1
3. Moisan, E. and Girard, D. (2005). JLB. DOI:10.1189/jlb.0405190
4. Yu, YT., et. al. (2016). Journal of Biomedical Science. DOI: 10.1186/s12929-016-0234-7
5. Satelli A., et al. (2014). Cancer Research. DOI:10.1158/0008-5472.CAN-13-1739.
6. Satelli A., et al. (2014). Clinical Cancer Research. DOI:10.1158/1078-0432.CCR-14-0894.
7. Mitra, A., et al. (2015). IJC. DOI:10.1002/ijc.29382.
8. Noh H. et al. (2016). Oncotarget DOI: 10.18632/oncotarget.12458.
9. Satelli A. (2014). WIPO. WO 2014/138183 A1.
Featured Products

For any inquiry, please contact : OEM@abnova.com

For any inquiry, please contact
We have placed cookies on your device to make our website better. If you continue using our website, we assume you agree to it. You can learn more details here .